Rhodiola Rosea (Golden Root / Arctic Root)
SupplementThe medical score (68) and community score (74) are closely aligned. The slight superiority of the community score is explained by subjectively perceived stress reduction in everyday life [c1, c2], which is difficult to capture in strictly controlled RCT designs with small effect sizes [s1, s8].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Rhodiola rosea is the best-evidenced herbal adaptogen for stress-related fatigue: multiple RCTs show consistent, if modest, effects, and the EMA's herbal monograph formally recognises its traditional use. The effect is real but subtle — expect nothing dramatic, and give it 1–2 weeks before judging. 200–400 mg of standardised extract (3% rosavins, 1% salidroside) taken in the morning is the most clinically supported protocol; evening dosing causes sleep disturbances in a meaningful subset of users. Combining Rhodiola with SSRIs without medical oversight is an underappreciated risk that forums discuss far too casually.
Description
Plant-derived adaptogen from the root of Rhodiola rosea; reduces stress-related fatigue and supports mental performance according to several RCTs [s1, s2].
Rhodiola rosea L. (roseroot) is a perennial succulent native to arctic and subarctic mountain regions (Scandinavia, Siberia, Tibet). The dried rhizomes and roots have been used for centuries in traditional Russian and Scandinavian medicine [s13]. The pharmacologically relevant marker compounds are rosavin, rosarin, and rosin (cinnamyl alcohol glycosides, specific to R. rosea), as well as salidroside (phenylethanol glycoside, also present in other Rhodiola species) and tyrosol [s3, s4]. Standardized extracts are typically adjusted to 3% rosavins and 1% salidroside [s5]. Clinical studies demonstrate moderate efficacy for stress-related fatigue, burnout symptoms, and mild to moderate depression [s1, s2, s6]. A systematic review identified 11 controlled studies (10 RCTs, 1 CCT); three of five RCTs on mental fatigue and two of six RCTs on physical fatigue showed positive results [s1]. A more recent meta-analysis (2025) on endurance performance found significant effects on selected biomarkers, but no consistent improvement in overall endurance performance [s7]. Effect sizes are generally considered small to moderate [s8]. The substance is considered well tolerated at recommended doses; adverse effects are mostly mild and dose-dependent [s13, s14]. Interactions with serotonergic substances and certain antihypertensives have been reported [s9, s10].
Legal Status (DE)
In Germany, Austria, and Switzerland, Rhodiola rosea is marketable as an over-the-counter food supplement. The EMA's HMPC has adopted an EU herbal monograph recognizing "traditional use" for the relief of stress symptoms and fatigue [s13]. The BfR derives no risk potential from available human studies (100–1,800 mg extract/day) [s14]. Wild populations in Germany and Austria are protected by law; commercial products use cultivated or imported plant material [s15].
Mechanism of Action
Rhodiola rosea exerts its adaptogenic effect via several complementary mechanisms: 1. HPA axis modulation: Rosavin and salidroside attenuate excessive activation of the hypothalamic-pituitary-adrenocortical (HPA) axis and the sympatho-adrenal system (SAS), contributing to normalization of stress hormone levels (particularly cortisol) [s3, s4]. 2. Monoaminergic: Salidroside and tyrosol inhibit monoamine oxidase (MAO-A and MAO-B), slowing the degradation of serotonin, dopamine, and noradrenaline and increasing their availability in the CNS [s11]. This mechanism is discussed as a contributing factor to the antidepressant effect [s6]. 3. Antioxidant and cytoprotective: The active constituents reduce reactive oxygen species (ROS) and activate cellular defense pathways (including Hsp70, Nrf2 pathway), resulting in reduced cellular damage under stress conditions [s3]. 4. Neuroendocrine: In an RCT (n=60), an R. rosea extract (SHR-5, 576 mg/day) prevented further elevation of the cortisol awakening response pattern following acute stress [s2], supporting a direct effect on morning cortisol secretion. 5. Anti-inflammatory: Inhibition of pro-inflammatory cytokines (IL-6, CRP) was measured in athlete RCTs, but was not consistent across studies [s7]. The precise weighting of individual mechanisms in humans has not yet been conclusively established; available data are partly derived from animal studies and in vitro experiments [s3, s4].
Dosing
Stressbedingte Müdigkeit / Burnout
- Dose
- 200–400 mg standardized extract (3% rosavins, 1% salidroside)
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- 4–12 Wochen
- Timing
- Morning and/or midday, at least 30 minutes before breakfast on an empty stomach
- With food
- vermeiden
Leichte bis moderate Depression (adjuvant)
- Dose
- 340–680 mg/day SHR-5 extract
- Frequency
- 2× täglich (340 mg/Tag) oder 4× täglich (680 mg/Tag)
- Route
- oral
- Duration
- 6 Wochen
- Timing
- Morning and midday
- With food
- vermeiden
Kognitive und körperliche Leistung (Sportler)
- Dose
- 100–200 mg acutely or 600 mg/day chronically
- Frequency
- 1× täglich (chronisch) oder einmalig akut
- Route
- oral
- Duration
- 7 Tage (Loading) oder akut
- Timing
- 1 hour before exercise or cognitive demand
- With food
- optional
The BfR derives no risk potential from human studies using up to 1,800 mg extract/day [s14]. The EFSA recommends a daily intake of 200–400 mg extract [s14]. Higher doses are not better supported by clinical evidence and are associated with an increased risk of stimulatory adverse effects [s9].
Avoid evening administration due to possible stimulating effects (sleep disturbances) [s9, c4]. Morning intake on an empty stomach corresponds to the dosing protocol of most clinical studies [s2, s6]. Effects typically onset after 1–2 weeks of regular use [s5].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Schlaflosigkeit, innere Unruhe, Reizbarkeit Stimulatory component via monoamine oxidase inhibition; more frequent with evening administration or overdose [s9, s11]. | gelegentlich | leicht |
| Kopfschmerzen Described in user reports and listed as a common side effect by WebMD/Merck Manual [s9, s10]. | gelegentlich | leicht |
| Mundtrockenheit oder vermehrter Speichelfluss Listed by WebMD as an occasional side effect; mechanism unclear [s9]. | gelegentlich | leicht |
| Gastrointestinale Beschwerden (Übelkeit, Magendruck) Primarily at higher doses; rarely observed in clinical studies at recommended dosing [s13]. | gelegentlich | leicht |
| Schwindel Mentioned as a side effect in pharmacological reviews [s9]. | selten | leicht |
| Palpitationen (Herzrasen) Described in case reports and German user reports; to be considered a criterion for discontinuation [s9, c4]. | selten | moderat |
| Allergische Hautreaktionen Occasionally mentioned in German user reports; systematic data lacking [s9]. | selten | leicht |
Contraindications
Stimulatory and monoaminergic effects could trigger or exacerbate manic episodes [s10, s11].
Insufficient safety data; HMPC monograph does not recommend use during pregnancy and lactation [s13].
Additive MAO inhibition significantly increases risk of serotonin syndrome [s11].
Allergic reactions possible; use contraindicated [s13].
Immunomodulatory properties may exacerbate autoimmune reactions; Rhodiola may attenuate the effect of immunosuppressants [s10].
HMPC monograph does not recommend use in children under 12 years due to insufficient data [s13].
Interactions
Synergistic
Frequently reported as a positive combination in user accounts; potential additive alertness and focus effects, but no RCT evidence [c1].
Traditional stacking; synergistic stress reduction is discussed, but clinical evidence is lacking [s13].
Ashwagandha and Rhodiola complement each other as adaptogens for stress reduction and HPA axis regulation. Ashwagandha tends to be calming and cortisol-lowering, while Rhodiola is more stimulating and energy-promoting. The combination may offer complementary effects, but must be evaluated individually.
Rhodiola and Panax ginseng are combined traditionally and in modern nootropic stacks to additively improve energy, mental endurance, and cognitive performance. Both act adaptogenically via similar but not identical pathways.
The combination of Rhodiola and Bacopa monnieri is frequently used as a nootropic stack. Rhodiola may attenuate the lethargy that Bacopa can cause, while Bacopa complements the long-term cognitive effects. Users report synergistic effects on mood and cognition.
Rhodiola and Schisandra combine their adaptogenic effects for stress modulation. Both inhibit stress-activated protein kinases and cortisol, yielding complementary effects on stress resistance.
Caution
Rhodiola inhibits MAO and increases serotonin levels; combined use may increase the risk of serotonin syndrome [s9, s11].
An interaction between Rhodiola and losartan has been described; clinical relevance is unclear [s9].
Possible additive effect on blood coagulation; caution with concomitant warfarin or aspirin use [s10].
Rhodiola may have immunostimulatory effects and attenuate the efficacy of immunosuppressants [s10].
Possible additive blood glucose-lowering effects; monitoring recommended [s10].
Since Ashwagandha has sedating and Rhodiola has stimulating effects, concurrent use may result in opposing effects. The combination is not suitable for everyone and should be trialed individually.
Caffeine considerably amplifies the stimulating effect of Rhodiola. The combination may lead to overstimulation, sleep disturbances, palpitations, or anxiety, particularly at higher doses of both substances.
Rhodiola increases serotonin availability through MAO inhibition; in combination with 5-HTP, serotonin levels may rise excessively, potentially precipitating serotonin syndrome.
Studies
Tier A — High Evidence
Outcome: Physical and mental fatigue in various populations
Effect Size: 3/5 RCTs on mental fatigue positive; 2/6 RCTs on physical fatigue positive; effect sizes not reported consistently
Outcome: Pines Burnout Scale, MADRS, SF-36, cortisol awakening response
Effect Size: Significant reduction in burnout symptoms and cortisol awakening response vs. placebo
Outcome: Endurance performance (time to exhaustion, time trial) and biomarkers (CK, CRP, IL-6, MDA, SOD)
Effect Size: Significant effects on individual biomarkers; no consistent improvement in overall endurance performance
Outcome: HAMD score in mild to moderate depression
Effect Size: Significant improvement in both verum groups vs. placebo (p<0.05); 340 mg comparably effective to 680 mg
Outcome: Anaerobic muscular endurance (bench press), cognitive function (Stroop test)
Effect Size: Dose-dependent improvements in muscular endurance and Stroop test; effects small to moderate
Tier B — Moderate Evidence
Outcome: Burnout symptoms (MBI, Pines Scale), quality of life
Effect Size: Consistent improvement in burnout symptoms; no control group
Outcome: Mental performance, physical capacity, oxidative stress in healthy males
Effect Size: No significant improvement in mental or physical performance vs. placebo; reduced oxidative stress
Tier C — Low Evidence
Outcome: ROS reduction, neurite outgrowth in vitro
Effect Size: Significant antioxidant effects in cell models; limited clinical transferability (retracted)
Community Evidence
Top reported benefits
- Reduction of stress-related fatigue and general exhaustion
- Calmer, more composed baseline mood
- Improved focus and concentration (especially in combination with caffeine)
- Subjectively increased resilience during periods of stress
- Mild mood-elevating effect
Top reported issues
- Insomnia and inner restlessness with evening administration or high doses
- No noticeable effect in a subset of users
- Headaches, sometimes at treatment initiation
- Effect is subtle and difficult to distinguish from placebo
- Discontinuation effects occasionally reported (rebound fatigue)
Several users report sleep disturbances and irritability at doses above 400 mg or with evening administration [c2, c4]. Combination with SSRIs is practiced in forums, sometimes without awareness of the serotonin syndrome risk; this represents a relevant safety signal [c3, s9]. A subset of users reports that Rhodiola appears effective only in combination with other nootropics [c1].
Scientific Sources
- Rhodiola rosea for physical and mental fatigue: a systematic review
Ishaque S, Shamseer L, Bukutu C, et al. (2012). BMC Complementary and Alternative MedicineAPMID:22643043DOI - Rhodiola - Special Subjects (Dietary Supplements)
Merck Manual Editorial Staff (2024). Merck Manual Professional EditionBLink - Pharmacological Mechanisms of Rhodiola Rosea and Salidroside
Nature Index / Panossian A (2022). Nature Index TopicsBLink - Effects of Rhodiola rosea supplementation on mental performance, physical capacity, and oxidative stress biomarkers in healthy men
Parisi A, Tranchita E, Duranti G, et al. (2016). Journal of Sport and Health ScienceAPMID:29276627DOI - European Union herbal monograph on Rhodiola rosea L., rhizoma et radix (Revision 1)
EMA/HMPC (2022). European Medicines Agency (EMA)ALink - Gestresst, müde, erschöpft – entspannter mit Rhodiola oder Rosenwurz?
Verbraucherzentrale Bundesverband / BfR (2023). Verbraucherzentrale.deBLink - Comprehensive profiling of Rhodiola rosea roots and corresponding products: phytochemical insights and modulation of neuroinflammation in BV2 microglial cell model
Author names not available in search results (2025). Frontiers in PharmacologyCDOI - A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen
Darbinyan V, Kteyan A, Panossian A, et al. (2000). PhytomedicineAPMID:11081993DOI - Rhodiola Rosea Extract Counteracts Stress in an Adaptogenic Response Curve Manner via Elimination of ROS and Induction of Neurite Outgrowth [RETRACTED]
Agapouda A, Grimm A, Eckert A, et al. (2022). Oxidative Medicine and Cellular LongevityCPMID:35096252DOI - The Science Behind Rhodiola Rosea: Adaptogenic Properties Explained
Panossian A, Wikman G, Sarris J (2023). nbinno.com (Übersichtsartikel, kein Peer-Review)CLink - Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms
Kasper S, Dienel A (2017). Neuropsychiatric Disease and TreatmentBPMID:28367054DOI - Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression
Darbinyan V, Aslanyan G, Amroyan E, et al. (2007). Nordic Journal of PsychiatryAPMID:17990195DOI - The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis
Author names not available in search results (2025). Frontiers in NutritionADOI - Dose-Response Effects of Short-Term Rhodiola rosea (Golden Root Extract) Supplementation on Anaerobic Exercise Performance and Cognitive Function in Resistance-Trained Athletes: A Randomized, Crossover, Double-Blind, and Placebo-Controlled Study
Author names not available in search results (2025). PMC / NutrientsALink - Rhodiola: Usefulness and Safety
NCCIH Staff (2023). National Center for Complementary and Integrative Health (NCCIH)BLink
Community Sources
Storage
Unopened
Store in a dry, cool (15–25 °C), light-protected environment.
Opened
Keep container tightly closed; avoid moisture and light for powder/capsule forms.
Notes
Extracts with defined active compound contents (3% rosavins, 1% salidroside) are more sensitive to light and moisture than crude plant powders. Refrigeration is not required but is not harmful.